Vanguard Investments Australia
PCVX icon

Vanguard Investments Australia’s Vaxcyte PCVX Stock Holding History

Vanguard Investments Australia’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.74M Hold
29,942
– – ﹤0.01% 983
2026
Q1 		$1.74M Buy
+29,942
New +$1.63M 0.01% 913

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Investments Australia's PCVX Position: Q2 2026 in Review

Vanguard Investments Australia held its Vaxcyte (PCVX) position steady in Q2 2026 at 29,942 shares worth $1.74M. The position accounts for ﹤0.01% of the portfolio, ranked #983.

Vanguard Investments Australia first reported a position in PCVX in Q1 2026 and has held it in 2 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Vanguard Investments Australia held 29,942 shares of Vaxcyte worth $1.74M as of Q2 2026.
  • Vanguard Investments Australia left its Vaxcyte share count unchanged in Q2 2026.
  • Vaxcyte made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #983 holding.
  • Vanguard Investments Australia first reported a position in Vaxcyte in Q1 2026 and has held it in 2 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.